HA
ABBV icon

Homestead Advisers’s AbbVie ABBV Stock Holding History

Homestead Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95.3M Sell
439,401
-91,300
-17% -$20.3M 2.56% 9
2025
Q4 		$121M Sell
530,701
-125,559
-19% -$28.6M 3.21% 6
2025
Q3 		$152M Sell
656,260
-57,600
-8% -$11.7M 3.62% 2
2025
Q2 		$133M Buy
713,860
+1,200
+0.2% +$223K 3.14% 4
2025
Q1 		$149M Hold
712,660
– – 3.66% 2
2024
Q4 		$127M Buy
712,660
+26,800
+4% +$4.93M 3.05% 7
2024
Q3 		$135M Sell
685,860
-500
-0.1% -$93.3K 3.22% 5
2024
Q2 		$118M Sell
686,360
-12,100
-2% -$2M 2.9% 8
2024
Q1 		$127M Sell
698,460
-1,100
-0.2% -$190K 2.98% 5
2023
Q4 		$108M Sell
699,560
-45,800
-6% -$6.68M 2.77% 7
2023
Q3 		$111M Sell
745,360
-121,127
-14% -$17.8M 3.09% 6
2023
Q2 		$120M Buy
866,487
+79,627
+10% +$11.7M 3.18% 8
2023
Q1 		$125M Sell
786,860
-17,000
-2% -$2.6M 3.5% 3
2022
Q4 		$130M Sell
803,860
-22,500
-3% -$3.45M 3.47% 3
2022
Q3 		$111M Sell
826,360
-3,700
-0.4% -$531K 3.36% 6
2022
Q2 		$127M Hold
830,060
– – 3.6% 5
2022
Q1 		$135M Buy
830,060
+12,700
+2% +$1.84M 3.29% 6
2021
Q4 		$111M Sell
817,360
-6,300
-0.8% -$744K 2.55% 10
2021
Q3 		$88.8M Buy
823,660
+3,200
+0.4% +$366K 2.16% 14
2021
Q2 		$92.4M Buy
820,460
+5,900
+0.7% +$664K 2.14% 13
2021
Q1 		$88.2M Buy
814,560
+49,000
+6% +$5.24M 2.11% 13
2020
Q4 		$82M Sell
765,560
-18,500
-2% -$1.78M 2.03% 14
2020
Q3 		$68.7M Buy
784,060
+15,200
+2% +$1.43M 1.88% 16
2020
Q2 		$75.5M Buy
768,860
+303,498
+65% +$26.7M 1.94% 17
2020
Q1 		$35.5M Buy
+465,362
New +$39.6M 1.05% 38
2017
Q1 		– Sell
-1,681,000
Closed -$105M – 96
2016
Q4 		$105M Sell
1,681,000
-408,281
-20% -$24.9M 1.66% 22
2016
Q3 		$132M Hold
2,089,281
– – 2.18% 11
2016
Q2 		$129M Hold
2,089,281
– – 2.22% 12
2016
Q1 		$119M Buy
+2,089,281
New +$116M 2.13% 15

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Homestead Advisers's ABBV Position: Q1 2026 in Review

Homestead Advisers reduced its AbbVie (ABBV) stake by 17% in Q1 2026, selling an estimated $20.3M and leaving 439,401 shares worth $95.3M. The position accounts for 2.56% of the portfolio, ranked #9.

Homestead Advisers first reported a position in ABBV in Q1 2016 and has held it in 29 quarters since. The position peaked at $152M in Q3 2025. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Homestead Advisers held 439,401 shares of AbbVie worth $95.3M as of Q1 2026.
  • Homestead Advisers sold 91,300 AbbVie shares in Q1 2026, an estimated $20.3M.
  • AbbVie made up 2.56% of Homestead Advisers's portfolio in Q1 2026, its #9 holding.
  • Homestead Advisers first reported a position in AbbVie in Q1 2016 and has held it in 29 quarters since.
  • Homestead Advisers's AbbVie position peaked at $152M in Q3 2025.
  • 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Homestead Advisers's 13F filing for Q1 2026, filed 8 May 2026.